Skip to content
Menu

Morgan Stanley Maintains Overweight on Eikon Therapeutics, Lowers Price Target to $30

Benzinga Newsdesk 35 minutes ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Morgan Stanley analyst Sean Laaman maintains Eikon Therapeutics (NASDAQ:EIKN) with a Overweight and lowers the price target from $32 to $30.

Morgan Stanley analyst Sean Laaman maintains Eikon Therapeutics (NASDAQ:EIKN) with a Overweight and lowers the price target from $32 to $30.

Read at benzinga.com